Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: Role of acrR mutations

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 5, 2001, Pages 1515-1521

  Wang, H ^a   Dzink Fox, J L ^a   Chen, M ^a   Levy, S B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BACTERIAL INFECTION; CHINA; DRUG EFFECT; ESCHERICHIA COLI; GENE MUTATION; GENETIC ANALYSIS; GENETIC COMPLEMENTATION; HOSPITAL INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; CHINA; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; HUMANS; LIPOPROTEINS; MEMBRANE TRANSPORT PROTEINS; SOLVENTS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0035038579     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.5.1515-1521.2001     Document Type: Article

References (61)

1. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections
2. Molecular characterization of the soxRS genes of Escherichia coli: Two genes control a superoxide stress regulon
3. Activation of multiple antibiotic resistance and binding of stress-inducible promoters by Escherichia coli Rob protein
4. Analysis of mutations involved in fluoroquinolone resistance of in vivo and in vitro mutants of Escherichia coli
5. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli
6. Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA
7. Rapid development of ciprofloxacin resistance in methicillin-susceptiable and -resistant Staphylococcus aureus
8. Mechanisms of resistance to quinolones
9. Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli
10. Cross-resistance to fluoroquinolone in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: Decreased drug accumulation associated with membrane changes in addition to OmpF reduction
11. marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli
12. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli
13. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones
14. Two complementation groups mediate tetracycline resistance determined by Tn10
15. Contributions of individual mechanisms to fluoroquinolone resistance in 36 strains of Escherichia coli isolated from humans and animals
16. Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: Involvement of a non-plasmid-determined efflux of tetracycline
17. Activation of oxidative stress genes by mutations at soxQ/cfxB/marA locus in Escherichia coli
18. Positive control of a global antioxidant defense regulon activated by superoxide-generating agents in Escherichia coli
19. Genetic evidence for a role of parC mutation in the development of high-level fluoroquinolone resistance in Escherichia coli
20. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli
21. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro
22. Quinolone mode of action - New aspects
23. Mechanisms of fluoroquinolone resistance
24. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli
25. Topoisomerase IV is a target of quinolones in Escherichia coli
26. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin
27. Mutants of Escherichia coli DNA topoisomerase IV parC gene
28. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
29. The local repressor AcrR plays a modulating role in the regulation of acrAB genes of Escherichia coli by global stress signals
30. High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA
31. Multidrug resistance following expression of the Escherichia coli marA gene in Mycobacteriurn smegmatis
32. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center
33. Overexpression of the robA gene increase organic solvent tolerance and multiple antibiotic and heavy metal ion resistance in Escherichia coli
34. gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli
35. Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers
36. Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli
37. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump
38. Overexpression of the marA or soxS regulatory, gene in clinical topoisomerase mutants of Escherichia coli
39. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: Proof provided by typing with a DNA probe
40. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants
41. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction
42. Construction and use of a new broad-host-range lacZ transcriptional fusion vector, pHRP309, for Gram-negative bacteria
43. Molecular analysis of fluoroquinolone-resistance in Escherichia coli. On the aspect of gyrase and multiple antibiotic resistance (mar) genes
44. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections
45. Quinolone resistance in clinical practice: Occurrence and importance
46. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations
47. AcrD of Escherichia coli is an aminoglycoside efflux pump
48. Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998
49. Mechanisms involved in the development of resistance to fluoroquinolone in Escherichia coli
50. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
51. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli
52. Association between double mutations in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs
53. Resistant rates of Gram-negative bacilli to 12 antibiotics by using Etest
54. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli
55. Two divergently transcribed genes, soxR and soxS, control a superoxide response regulon of Escherichia coli
56. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli
57. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli
58. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli
59. Quinolone resistant mutations of the gyrase gyrA gene of Escherichia coli
60. Susceptibility of 5374 isolates to 18 antibiotics from 5 hospitals in Beijing